Resumen

The oral administration of a compound, selected from endogenous polyamines (putrescine, spermidine, spermine), 1,3-propanediamine, the pharmaceutically acceptable solvates and salts thereof and the bioprecursor amides of same, to genetically alcoholic mice (from the UChB strain from the University of Chile) causes a significant reduction in alcohol consumption. The activity of said compound continues for a certain amount of time following the treatment period. Moreover, there is practically zero disulfiram-type adverse effect, which is advantageous given the unpleasant aspect of using certain antialcoholic agents, such as calcium cyanamide and said disulfiram. Therefore, the inventive compounds can be used to prepare medicaments that are used for the therapeutic and/or prophylactic treatment of alcoholism in humans.